Vasopressor
Phase 3Small molecule
Vasopressor is one of 46 small molecule programs targeting Sepsis. It is currently in Phase 3.
2
Indications
7
Total Trials
2
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
308 competitors in Sepsis
#DrugCompanyPhaseTrials
1Vasopressor
MMedical University of Vienna
Phase 3
Corlanor
AmgenPreclinical
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Primaxin
PfizerPreclinical
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Aquasol a
BBandim Health Project
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sepsis1 trial
Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis
Active, not recruiting·—·Phase 3·NCT04569942·1,000 enrolled
Hemodynamic1 trial
Hemodynamic Management in Autologous Blood Collection for CABG Surgery
Completed·—·Phase 4·NCT06835257·40 enrolled
Septic Shock1 trial
The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation
Completed·—·N/A·NCT03020407·211 enrolled
Intraoperative1 trial
Anticoagulation1 trial
No Monitoring of Post-filter Ionized Calcium in Regional Citrate Anticoagulation
Completed·—·N/A·NCT04792424·50 enrolled
2 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Vasopressor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMedical University of Vienna